.Nature Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after an average consequence of 11 months, individuals with metastatic gastrointestinal tumors who received biomarker-matched therapies based upon distributing tumor DNA profiling presented a higher medical perk than those obtaining unmatched therapy.